Page 5 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

Burden associated with BC recurrence

 Patients with eBC who experienced recurrence
 required more costly care than patients who did not develop recurrent disease 22,23

 Contralateral and locoregional events
 they are associated with high costs of further surgery and/or radical radiotherapy 24

 a high proportion of patients go on to experience distant recurrence within
5 years 24
 this incurs the additional costs of treating metastatic disease 24

Productivity losses due to BC

 BC represents the greatest productivity loss among
all cancers in the female population 25
 the incidence of BC is at its peak during

mid-working age in the working-age population 25
 it is the most common and fastest growing cancer 25

 BC progression leads to
 diminished likelihood of employment 26
 increased workplace hours missed 26
 increased cost burden 26

 BC workers experience a great influence of the side
effects of anticancer drugs on

 quality of life 27
 absenteeism 27
 presenteeism 27

 There is substantial loss of productivity in patients

with mBC compared with patients living with
non-metastatic disease 26,27

M-AE-00000086 5